March 15 (Reuters) - Glenmark Pharmaceuticals Ltd: * Says Ankleshwar plant has received the EIR (Establishment Inspection Report) issued by the FDA Source text: Clarification relating to an article on ...

At the operational level, Glenmark Pharma's earnings before interest, taxes, depreciation and amortisation (EBITDA) for the March quarter rose 26.7 per cent to ₹504.2 crore, compared to ₹398 crore in ...

Glenmark Life Sciences‘ net profit for the second quarter of fiscal year 2025 fell 20% year-on-year (YoY) to ₹95.32 Crore. This is due to the temporary closure of its Gujarat manufacturing site.

“Our performance in the quarter was driven by Generic API and the CDMO businesses. Geographically, the US, Europe, RoW and India markets spearheaded this growth. We remain focused on our strategic ...

Shares of Glenmark Life Sciences surged over 9 percent in early trade on April 28, a day after the company posted a robust set of earnings for the March quarter, reflecting growth across all ...

(Reuters) - Indian drugmaker Glenmark Life Sciences posted a fall in second-quarter profit on Thursday, hurt by the temporary closure of a manufacturing facility in the western state of Gujarat. The ...